Ngenla is a long-acting human growth hormone (somatrogon) designed to treat growth hormone deficiency (GHD) in both children and adults. It works by supplementing the natural growth hormone in individuals who produce insufficient amounts, thereby promoting growth and addressing growth-related disorders.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for ngenla include growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, and being small for gestational age. Growth hormone deficiency is characterized by insufficient growth hormone production, resulting in stunted growth in both children and adults. Ngenla is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by different groups of patients, including pediatric and adult populations.
The ngenla market research report is one of a series of new reports that provides ngenla market statistics, including ngenla industry global market size, regional shares, competitors with a ngenla market share, detailed ngenla market segments, market trends and opportunities, and any further data you may need to thrive in the ngenla industry. This ngenla market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to rising demand for convenient treatment options, growth in the pediatric population worldwide, increasing R&D investments in biologics, expansion of healthcare insurance coverage, and growing focus on personalized medicine. Major trends in the forecast period include the development of next-generation growth hormone therapies, expansion into untapped markets, integration of AI in patient monitoring, growth of telemedicine for patient management, and increasing regulatory focus on patient safety.
The increasing prevalence of pediatric growth hormone deficiency (GHD) is expected to contribute significantly to the growth of the ngenla market. Pediatric GHD is a condition marked by inadequate secretion of growth hormone, which affects physical development and overall health in children. This rise in prevalence is attributed to improved awareness, enhanced diagnostic capabilities, and increased global access to healthcare services. Ngenla, a long-acting recombinant human growth hormone (somatrogon), addresses pediatric GHD by providing sustained and consistent growth hormone release through once-weekly injections. This reduces the treatment burden of daily administration, enhances adherence, and effectively stimulates growth and development in children with insufficient growth hormone production. For instance, the National Library of Medicine (NLM) reported in January 2024 that growth hormone deficiency in children is a rare condition, with its prevalence estimated at 1 in 3,500 to 1 in 10,000, depending on diagnostic criteria and stimulation test thresholds. As a result, the rising prevalence of pediatric GHD is driving the demand for ngenla.
A significant trend in the ngenla market is the focus on advancements in long-acting growth hormone therapies, which aim to improve treatment adherence and deliver better outcomes for both pediatric and adult patients with growth hormone deficiency. These therapies are designed for sustained hormone release, reducing injection frequency and enhancing patient compliance. For example, in June 2023, Pfizer Inc. and OPKO Health Inc. received US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog. This treatment is indicated for pediatric patients aged three years and older experiencing growth failure due to insufficient endogenous growth hormone secretion.
In July 2024, OPKO Health, Inc., a US-based biopharmaceutical and diagnostics company, entered into a partnership with HealthCare Royalty (HCRx) through non-dilutive note purchase agreements. This arrangement is secured by OPKO’s profit share payments from Pfizer related to NGENLA, a treatment for pediatric growth hormone deficiency. The agreement enables OPKO to retain a significant portion of its profit shares in the short term while offering potential long-term financial advantages. HealthCare Royalty (HCRx) is a US-based company specializing in royalty acquisitions.
The key company operating in the ngenla market is Pfizer Inc.
North America was the largest region in the ngenla market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ngenla report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ngenla market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The ngenla market consists of sales of prefilled injection pens and somatrogon solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for ngenla include growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, and being small for gestational age. Growth hormone deficiency is characterized by insufficient growth hormone production, resulting in stunted growth in both children and adults. Ngenla is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by different groups of patients, including pediatric and adult populations.
The ngenla market research report is one of a series of new reports that provides ngenla market statistics, including ngenla industry global market size, regional shares, competitors with a ngenla market share, detailed ngenla market segments, market trends and opportunities, and any further data you may need to thrive in the ngenla industry. This ngenla market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to rising demand for convenient treatment options, growth in the pediatric population worldwide, increasing R&D investments in biologics, expansion of healthcare insurance coverage, and growing focus on personalized medicine. Major trends in the forecast period include the development of next-generation growth hormone therapies, expansion into untapped markets, integration of AI in patient monitoring, growth of telemedicine for patient management, and increasing regulatory focus on patient safety.
The increasing prevalence of pediatric growth hormone deficiency (GHD) is expected to contribute significantly to the growth of the ngenla market. Pediatric GHD is a condition marked by inadequate secretion of growth hormone, which affects physical development and overall health in children. This rise in prevalence is attributed to improved awareness, enhanced diagnostic capabilities, and increased global access to healthcare services. Ngenla, a long-acting recombinant human growth hormone (somatrogon), addresses pediatric GHD by providing sustained and consistent growth hormone release through once-weekly injections. This reduces the treatment burden of daily administration, enhances adherence, and effectively stimulates growth and development in children with insufficient growth hormone production. For instance, the National Library of Medicine (NLM) reported in January 2024 that growth hormone deficiency in children is a rare condition, with its prevalence estimated at 1 in 3,500 to 1 in 10,000, depending on diagnostic criteria and stimulation test thresholds. As a result, the rising prevalence of pediatric GHD is driving the demand for ngenla.
A significant trend in the ngenla market is the focus on advancements in long-acting growth hormone therapies, which aim to improve treatment adherence and deliver better outcomes for both pediatric and adult patients with growth hormone deficiency. These therapies are designed for sustained hormone release, reducing injection frequency and enhancing patient compliance. For example, in June 2023, Pfizer Inc. and OPKO Health Inc. received US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog. This treatment is indicated for pediatric patients aged three years and older experiencing growth failure due to insufficient endogenous growth hormone secretion.
In July 2024, OPKO Health, Inc., a US-based biopharmaceutical and diagnostics company, entered into a partnership with HealthCare Royalty (HCRx) through non-dilutive note purchase agreements. This arrangement is secured by OPKO’s profit share payments from Pfizer related to NGENLA, a treatment for pediatric growth hormone deficiency. The agreement enables OPKO to retain a significant portion of its profit shares in the short term while offering potential long-term financial advantages. HealthCare Royalty (HCRx) is a US-based company specializing in royalty acquisitions.
The key company operating in the ngenla market is Pfizer Inc.
North America was the largest region in the ngenla market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ngenla report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ngenla market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The ngenla market consists of sales of prefilled injection pens and somatrogon solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ngenla Market Characteristics4. Ngenla Market Trends And Strategies5. Ngenla Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Ngenla Pricing Analysis & Forecasts30. Global Ngenla Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Ngenla Market32. Recent Developments In The Ngenla Market
3. Ngenla Market Biologic Drug Characteristics
6. Global Ngenla Growth Analysis And Strategic Analysis Framework
8. Ngenla Market Segmentation
9. Global Ngenla Epidemiology Of Clinical Indications
10. Ngenla Market Regional And Country Analysis
11. Asia-Pacific Ngenla Market
12. China Ngenla Market
13. India Ngenla Market
14. Japan Ngenla Market
15. Australia Ngenla Market
16. South Korea Ngenla Market
17. Western Europe Ngenla Market
18. UK Ngenla Market
19. Germany Ngenla Market
20. France Ngenla Market
21. Eastern Europe Ngenla Market
22. North America Ngenla Market
23. USA Ngenla Market
24. Canada Ngenla Market
25. South America Ngenla Market
26. Middle East Ngenla Market
27. Africa Ngenla Market
28. Ngenla Market Competitive Landscape And Company Profiles
29. Global Ngenla Market Pipeline Analysis
33. Ngenla Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Ngenla Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ngenla market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ngenla ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ngenla market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Growth Hormone Deficiency; Turner Syndrome; Prader-Willi; Small For Gestational Age2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric Patients; Adult Patients
Key Companies Profiled: Pfizer Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
